World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   164 records for 57 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6
Recruitment statusProspective RegistrationMain ID Public TitleDate of Registration
Not AvailableYesEUCTR2016-004322-42-Outside-EU/EEA
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)”.
31/08/2017
RecruitingYesDRKS00012686
Smartphone-based intervention (S.M.I.L.E.R.S.) to reduce mild to moderate depressive symptoms in Arabic-speaking clients
21/08/2017
RecruitingYesNCT03082976
Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region
27/02/2017
AuthorisedYesEUCTR2016-003370-40-GB
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease 09/12/2016
AuthorisedYesEUCTR2016-003467-19-BE
safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2016-003467-19-ESSafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease10/02/2017
AuthorisedEUCTR2016-003467-19-HUsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease25/11/2016
AuthorisedEUCTR2016-003467-19-GRsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease03/01/2017
AuthorisedEUCTR2016-003467-19-DKsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease16/02/2017
AuthorisedEUCTR2016-003467-19-SIsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease09/05/2017
AuthorisedEUCTR2016-003467-19-PTsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease14/12/2016
AuthorisedEUCTR2016-003467-19-FIsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease07/04/2017
AuthorisedEUCTR2016-003467-19-PLsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease06/04/2017
AuthorisedEUCTR2016-003467-19-NLsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease23/11/2016
AuthorisedEUCTR2016-003467-19-GBsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre / postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease07/11/2016
AuthorisedEUCTR2016-003467-19-CZsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease02/02/2017
AuthorisedEUCTR2016-003467-19-BGsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease07/12/2016
AuthorisedEUCTR2016-003467-19-ATsafety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease03/02/2017
20/10/2016
RecruitingYesNCT02941926
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC 20/10/2016
Not recruitingNoNCT02789527
Human Genomic Population Structure and Phenotype-genotype Variation in ADME Genes in Four Populations
11/05/2016
RecruitingYesISRCTN14425284
“MOVEdiabetes” a trial to promote physical activity for adults with type 2 diabetes in primary health care in Oman
10/04/2016
Not RecruitingYesDRKS00010245
Evaluation of web-based cognitive and behavioural therapeutic components and its change mechanisms for Arab people with posttraumatic stress disorder
30/03/2016
AuthorisedYesEUCTR2015-001963-37-LV
A long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2015-001963-37-SEA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease17/12/2015
AuthorisedEUCTR2015-001963-37-PTA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease10/02/2016
AuthorisedEUCTR2015-001963-37-ESA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn?s disease03/02/2016
AuthorisedEUCTR2015-001963-37-GRA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease01/06/2016
AuthorisedEUCTR2015-001963-37-FIA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease23/02/2017
AuthorisedEUCTR2015-001963-37-EEA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease07/12/2015
AuthorisedEUCTR2015-001963-37-DEA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease11/01/2016
AuthorisedEUCTR2015-001963-37-DKA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease22/02/2016
AuthorisedEUCTR2015-001963-37-SKA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease07/12/2015
AuthorisedEUCTR2015-001963-37-GBA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease29/12/2015
AuthorisedEUCTR2015-001963-37-HUA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease17/12/2015
AuthorisedEUCTR2015-001963-37-BGA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease13/04/2016
AuthorisedEUCTR2015-001963-37-CZA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease22/12/2015
AuthorisedEUCTR2015-001963-37-BEA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease10/02/2016
AuthorisedEUCTR2015-001963-37-ATA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease22/12/2015
AuthorisedEUCTR2015-001963-37-HRA long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease21/06/2016
01/12/2015
     
1 2 3 4 5 6
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.3 - Version history